BR0112674A - Inibidores n-[5-[[[5-alquil-2-oxazolil]metil] tio]-2tiazolil]carboxamida de quinases dependentes de ciclina - Google Patents

Inibidores n-[5-[[[5-alquil-2-oxazolil]metil] tio]-2tiazolil]carboxamida de quinases dependentes de ciclina

Info

Publication number
BR0112674A
BR0112674A BR0112674-1A BR0112674A BR0112674A BR 0112674 A BR0112674 A BR 0112674A BR 0112674 A BR0112674 A BR 0112674A BR 0112674 A BR0112674 A BR 0112674A
Authority
BR
Brazil
Prior art keywords
oxazolyl
thiazolyl
alkyl
dependent kinases
cyclin
Prior art date
Application number
BR0112674-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Raj N Misra
Hai-Yun Xiao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/727,957 external-priority patent/US6515004B1/en
Priority claimed from US09/746,060 external-priority patent/US6414156B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0112674A publication Critical patent/BR0112674A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR0112674-1A 2000-07-26 2001-05-09 Inibidores n-[5-[[[5-alquil-2-oxazolil]metil] tio]-2tiazolil]carboxamida de quinases dependentes de ciclina BR0112674A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61662700A 2000-07-26 2000-07-26
US09/727,957 US6515004B1 (en) 1999-12-15 2000-12-01 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US09/746,060 US6414156B2 (en) 1998-10-21 2000-12-22 Process for preparing azacycloalkanoylaminothiazoles
PCT/US2001/015081 WO2002010162A1 (en) 2000-07-26 2001-05-09 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases

Publications (1)

Publication Number Publication Date
BR0112674A true BR0112674A (pt) 2003-12-30

Family

ID=27417184

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112674-1A BR0112674A (pt) 2000-07-26 2001-05-09 Inibidores n-[5-[[[5-alquil-2-oxazolil]metil] tio]-2tiazolil]carboxamida de quinases dependentes de ciclina

Country Status (26)

Country Link
EP (1) EP1303513A1 (hr)
JP (1) JP2004509857A (hr)
KR (1) KR20030016429A (hr)
CN (1) CN100457753C (hr)
AR (1) AR030563A1 (hr)
AU (1) AU2001259704A1 (hr)
BG (1) BG65132B1 (hr)
BR (1) BR0112674A (hr)
CA (1) CA2417254A1 (hr)
CZ (1) CZ2003237A3 (hr)
EE (1) EE200300041A (hr)
EG (1) EG24409A (hr)
GE (1) GEP20043367B (hr)
HR (1) HRP20030116A2 (hr)
HU (1) HUP0303698A2 (hr)
IL (2) IL153591A0 (hr)
LV (1) LV13037B (hr)
MX (1) MXPA03000774A (hr)
MY (1) MY129635A (hr)
NO (1) NO20030394L (hr)
PL (1) PL365170A1 (hr)
SI (1) SI21099A (hr)
SK (1) SK18392002A3 (hr)
TW (1) TWI302533B (hr)
WO (1) WO2002010162A1 (hr)
YU (1) YU4903A (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
PE20030968A1 (es) 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
EP2311818B1 (en) * 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
JP2006500391A (ja) 2002-09-04 2006-01-05 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
RU2380369C9 (ru) 2002-09-04 2011-07-10 Шеринг Корпорейшн Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы
ATE377600T1 (de) 2002-09-23 2007-11-15 Schering Corp Imidazopyrazine als cdk-inhibitoren
JP2006503838A (ja) 2002-09-23 2006-02-02 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
EP1555264A1 (en) * 2004-01-15 2005-07-20 Sireen AG Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
CA2619790A1 (en) 2005-08-17 2007-02-22 Schering Corporation Novel high affinity thiophene-based and furan-based kinase ligands
ATE478852T1 (de) 2005-09-09 2010-09-15 Schering Corp Neue 4-cyano-, 4-amino-, und 4- aminomethylderivative von pyrazoloä1,5- aüpyridinen, pyrazoloä1,5-cüpyrimidinen und 2h- indazolverbindungen und 5-cyano-, 5-amino- und 5- aminomethylderivative von imidazoä1,2-aüpyridinen,und imidazoä1,5-aüpyrazinverbindungen als inhibitoren der cyclinabhänggen kinase
AR056206A1 (es) 2005-10-06 2007-09-26 Schering Corp Pirazolpirimidinas como inhibidores de protein quinasas
EP2044066A2 (en) * 2006-06-06 2009-04-08 Bristol-Myers Squibb Company Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
KR20090075873A (ko) 2006-10-31 2009-07-09 쉐링 코포레이션 아닐리노피페라진 유도체 및 이의 사용방법
AR063531A1 (es) 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
WO2008140724A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
EP2831282B1 (en) 2012-03-30 2018-07-04 Merck Sharp & Dohme Corp. Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
WO2015081867A1 (zh) * 2013-12-04 2015-06-11 杭州民生药物研究院有限公司 吉西他滨衍生物、含该衍生物的组合物及所述衍生物的制药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
DE69923681T2 (de) * 1998-06-18 2006-01-12 Bristol-Myers Squibb Co. Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
HRP20030116A2 (en) 2005-02-28
NO20030394D0 (no) 2003-01-24
BG107468A (en) 2004-01-30
SK18392002A3 (sk) 2003-09-11
EP1303513A1 (en) 2003-04-23
CA2417254A1 (en) 2002-02-07
TWI302533B (en) 2008-11-01
IL153591A0 (en) 2003-07-06
YU4903A (sh) 2006-03-03
BG65132B1 (bg) 2007-03-30
MXPA03000774A (es) 2003-09-10
GEP20043367B (en) 2004-06-10
PL365170A1 (en) 2004-12-27
LV13037B (en) 2003-11-20
EE200300041A (et) 2005-04-15
SI21099A (sl) 2003-06-30
KR20030016429A (ko) 2003-02-26
WO2002010162A1 (en) 2002-02-07
JP2004509857A (ja) 2004-04-02
CN1444584A (zh) 2003-09-24
CN100457753C (zh) 2009-02-04
EG24409A (en) 2009-05-20
HUP0303698A2 (hu) 2004-04-28
MY129635A (en) 2007-04-30
IL153591A (en) 2009-07-20
AR030563A1 (es) 2003-08-27
NO20030394L (no) 2003-03-03
CZ2003237A3 (cs) 2003-06-18
AU2001259704A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
BR0112674A (pt) Inibidores n-[5-[[[5-alquil-2-oxazolil]metil] tio]-2tiazolil]carboxamida de quinases dependentes de ciclina
PT1240165E (pt) Inibidores n-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]carboxamida de quinases dependentes da ciclina
BR0016424A (pt) Inibidores de n-[5-[[[5-alquiil-2-oxazolil]metil]-tio]-2-tiazolil]carbox amida de cinases dependentes de ciclina
NO20025450D0 (no) Ny farmasöytisk sammensetning
GB0005251D0 (en) Therapeutic compounds
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
AP1398A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
NO20023486L (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
LT2003001A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
HUP0300298A2 (hu) 4-[Piperazinil-8-(kinolinil-metil)]benzamid-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
SE9902937D0 (sv) Pharmaceutical compositions
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
UY26732A1 (es) N-(5-(5-alquil-2-oxazolil)metil)tio)-2- tiazolil) carboxamidas inhibidoras de cinasa dependientes de la ciclina
ECSP003821A (es) Inhibidores de n-(5(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina
ECSP003826A (es) Inhibidores de n-(5(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina
TH62250A (th) ตัวยับยั้ง n-[5-[[[5-แอลคิล-2-ออกซาโซลิล]เมธิล]ไธออล]-2-ไธแอโซลิล]- คาร์บอกแซมีด ของไซคลินดีเพนเดนท์ไคเนส
FR2804867B1 (fr) Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
UY25369A1 (es) Procedimiento para preparar inhibidores de proteasa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]